Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route

US9187568B2 · kind B2 · utility

Assignee

• STALLERGENES S.A. · FR

Inventors

• Thierry Batard · Versailles, FR
• Philippe Moingeon · Verrières-le-Buisson, FR
• Laurent Mascarell · Paris, FR
• Aline Zimmer · Groß-Gerau, DE
• Emmanuel Nony · Antony, FR

Key dates

• Filing date: May 7, 2010
• Grant date: Nov 17, 2015
• Expiry date: Oct 2, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.